Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains.
Lilly
since
auto-detected in 362 stories
72 days ago
Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains.
73 days ago
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.
3 months ago
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Zepbound and Mounjaro have now underperformed expectations for two straight quarters.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Zepbound and Mounjaro have now underperformed expectations for two straight quarters.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Zepbound and Mounjaro have now underperformed expectations for two straight quarters.
|← first ← previous page 3 of 4 next → last →|